TMS AND BOTULINUM TOXIN IN POST-STROKE UPPER LIMB SPASTICITY
NCT: NCT07624149 · COMPLETED
Brief Summary
Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper limb functions and spasticity have been investigated. However, the clinical effects of different TMS protocols combined with botulinum toxin-A (BTX-A) treatment and which protocol may be more effective remain unclear. The aim of this observational study is to compare the clinical effects of different TMS protocols in patients with post-stroke upper limb spasticity receiving BTX-A treatment and to evaluate the most appropriate TMS protocol.
Frequently Asked Questions
What is TMS AND BOTULINUM TOXIN IN POST-STROKE UPPER LIMB SPASTICITY?
TMS AND BOTULINUM TOXIN IN POST-STROKE UPPER LIMB SPASTICITY is a clinical trial registered under NCT07624149. Current status: COMPLETED.
What is the status of NCT07624149?
The current status of NCT07624149 (TMS AND BOTULINUM TOXIN IN POST-STROKE UPPER LIMB SPASTICITY) is: COMPLETED.
When did TMS AND BOTULINUM TOXIN IN POST-STROKE UPPER LIMB SPASTICITY start?
TMS AND BOTULINUM TOXIN IN POST-STROKE UPPER LIMB SPASTICITY started on 2025-01-20.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.